MX2021012335A - Anticuerpos humanos que se unen a ret y metodos de uso de los mismos. - Google Patents

Anticuerpos humanos que se unen a ret y metodos de uso de los mismos.

Info

Publication number
MX2021012335A
MX2021012335A MX2021012335A MX2021012335A MX2021012335A MX 2021012335 A MX2021012335 A MX 2021012335A MX 2021012335 A MX2021012335 A MX 2021012335A MX 2021012335 A MX2021012335 A MX 2021012335A MX 2021012335 A MX2021012335 A MX 2021012335A
Authority
MX
Mexico
Prior art keywords
ret
antibodies
conditions
signaling
activation
Prior art date
Application number
MX2021012335A
Other languages
English (en)
Inventor
Christopher Daly
Nicholas Papadopoulos
Gavin Thurston
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2021012335A publication Critical patent/MX2021012335A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona anticuerpos completamente humanos que se unen al receptor de tirosina cinasa RET, composiciones que comprenden los anticuerpos y métodos de uso. Los anticuerpos de la invención son útiles para tratar enfermedades, trastornos o afecciones asociadas con la expresión, activación o señalización del gen del receptor de tirosina cinasa RET, o una forma reordenada del mismo, incluyendo las afecciones cancerosas y el dolor asociado con el cáncer, o para aliviar el dolor asociado con otras afecciones atribuidas, al menos en parte, por la expresión, activación o señalización por RET. Los anticuerpos específicos para RET pueden ser útiles para ralentizar el crecimiento de células tumorales o la proliferación de células tumorales y también para aliviar el dolor asociado con el cáncer y otras afecciones. Los anticuerpos también pueden ser útiles para el diagnóstico de una enfermedad, trastorno o afección asociada con la activación o señalización por RET.
MX2021012335A 2019-04-10 2020-04-09 Anticuerpos humanos que se unen a ret y metodos de uso de los mismos. MX2021012335A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832218P 2019-04-10 2019-04-10
PCT/US2020/027554 WO2020210551A1 (en) 2019-04-10 2020-04-09 Human antibodies that bind ret and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2021012335A true MX2021012335A (es) 2021-11-12

Family

ID=70554175

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012335A MX2021012335A (es) 2019-04-10 2020-04-09 Anticuerpos humanos que se unen a ret y metodos de uso de los mismos.

Country Status (11)

Country Link
US (1) US20220185900A1 (es)
EP (1) EP3953390A1 (es)
JP (2) JP7511576B2 (es)
KR (1) KR20210150509A (es)
CN (1) CN113993898A (es)
AU (1) AU2020270966A1 (es)
CA (1) CA3134258A1 (es)
IL (1) IL287067A (es)
MA (1) MA55615A (es)
MX (1) MX2021012335A (es)
WO (1) WO2020210551A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023008327A (es) 2021-01-15 2023-08-22 Seagen Inc Anticuerpos inmunomoduladores de anticuerpo-farmaco.
BR112023015561A2 (pt) 2021-02-03 2023-11-14 Univ Minnesota Compostos imunoestimuiladores e conjugados
WO2023144790A1 (en) * 2022-01-31 2023-08-03 Glaxosmithkline Intellectual Property (No.3) Limited Prevention and treatment of headaches
WO2023215740A1 (en) 2022-05-06 2023-11-09 Seagen Inc. Immunomodulatory antibody-drug conjugates
WO2024030577A1 (en) 2022-08-03 2024-02-08 Seagen Inc. Immunostimulatory anti-pd-l1-drug conjugates
EP4321522A1 (en) 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
JP2008546716A (ja) 2005-06-17 2008-12-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ＧＦＲα３抗体
EP1941909A4 (en) * 2005-10-24 2012-05-23 Takeda Pharmaceutical ANTICANCER DRUGS
CN102585002A (zh) 2006-06-02 2012-07-18 瑞泽恩制药公司 人il-6受体的高亲和力抗体
DK2387583T3 (en) 2009-01-14 2019-01-14 Ablynx Nv PULMONAL ADMINISTRATION OF VARIABLE IMMUNGLOBULIN SINGLE DOMAINS AND CONSTRUCTIONS THEREOF.
HUE035773T2 (en) 2009-06-05 2018-05-28 Ablynx Nv Trivalent human airway giant cell virus (hrsv) nanotubes for preventing and / or treating respiratory infections
EP2445936A1 (en) 2009-06-26 2012-05-02 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها

Also Published As

Publication number Publication date
AU2020270966A1 (en) 2021-10-28
MA55615A (fr) 2022-02-16
KR20210150509A (ko) 2021-12-10
CN113993898A (zh) 2022-01-28
JP2024024114A (ja) 2024-02-21
CA3134258A1 (en) 2020-10-15
JP2022527373A (ja) 2022-06-01
WO2020210551A1 (en) 2020-10-15
US20220185900A1 (en) 2022-06-16
IL287067A (en) 2021-12-01
EP3953390A1 (en) 2022-02-16
JP7511576B2 (ja) 2024-07-05

Similar Documents

Publication Publication Date Title
MX2021012335A (es) Anticuerpos humanos que se unen a ret y metodos de uso de los mismos.
WO2019094642A8 (en) T cell manufacturing compositions and methods
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
MY151449A (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
MY169165A (en) Anti-pdgfr-beta antibodies and uses thereof
BR112012004546A8 (pt) Terapêutica por proteínas ligantes dll4-ligantes
PH12014502507A1 (en) Anti-angiogenesis therapy for the treatment of breast cancer
MX2014000555A (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
PH12015500084A1 (en) Rspo3 binding agents and uses thereof
EA033400B1 (ru) Антитело против cd3 и его применение
WO2011143318A3 (en) Anti-fgfr2 antibodies
MX2013010379A (es) Uso de inhibidores de receptores de la familia egfr en el tratamiento de canceres de mama refractarios a hormonas.
MX2020012799A (es) Composicion y metodo para tratar el cancer asociado con mutacion del egfr.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
WO2015049688A3 (en) Patient-specific immunotherapy for treating heterogeneous tumors
SA520420109B1 (ar) أجسام مضادة
MX2022003466A (es) Interrupción de los tejidos tumorales al dirigir la proteína de activación de fibroblastos (fap).
MX2021001508A (es) Proteínas de unión multiespecífica que se unen a her2, nkg2d y cd16 y métodos de uso.
MX2017011600A (es) Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata.
MX2021014164A (es) Moleculas de union a cd19 y usos de las mismas.
CL2022001715A1 (es) Tratamiento que involucra células efectoras inmunitarias modificadas genéticamente para expresar receptores de antígenos
MX336476B (es) Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado.
MX2022008061A (es) Composiciones y métodos para el tratamiento de enfermedades autoinmunes y cánceres por direccionamiento del miembro 8 de la superfamilia de inmunoglobulina(igsf8).
PL423203A1 (pl) Czynnik wzrostu do zastosowania w terapii przeciwnowotworowej dla pacjentów z nowotworami, w których przynajmniej część komórek wykazuje ekspresję EGFRvIII
PL427358A1 (pl) Czynnik wzrostu TGFβ (TGFβ2 lub TGFβ3) do zastosowania w terapii przeciwnowotworowej dla pacjentów z nowotworami, w których przynajmniej część komórek wykazuje ekspresję EGFRvIII